Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Luminex Announces Norovirus as a Launch Menu Assay for ARIES™

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
Assay is designed to test for both GI and GII genogroups.

Luminex Corporation has announced that norovirus will be the fourth assay in the launch menu for its new sample-to-answer system, ARIES™. The assay is designed to test for both GI and GII genogroups in a single, easy-to-use cassette.

The previously announced items in the five assay launch menu targeted for the ARIES system also include: Flu A&B/RSV, HSV 1&2, and Clostridium difficile (C. diff). Future menu items will be announced at a later date.

Norovirus is the most common cause of acute gastroenteritis worldwide. In the United States, it causes 20 million illnesses and contributes to over 50,000 hospitalizations each year. Because the infective dose of norovirus particles is very low, it is extremely contagious and can spread quickly especially in enclosed environments such as hospital wards, long-term care facilities, schools, and cruise ships. Norovirus is transmitted directly from person to person and indirectly via contaminated water and food or by touching contaminated surfaces.

"Typically norovirus and C. difficile are the two most likely causes of hospital acquired diarrhea. The presence and burden of norovirus in the hospital and other healthcare settings are often underappreciated," said Dr. Simon Goldenberg, Consultant Microbiologist and Infection Control Doctor, Guy's & St Thomas' Hospital. "Routine, rapid testing for norovirus as a frequent causative pathogen of hospital acquired diarrhea is essential in order to prevent outbreaks and hospital ward closures while reducing cost."

"Norovirus can be a very serious illness especially for the very young, the elderly and those that are immunocompromised," said Patrick J. Balthrop, president and chief executive officer of Luminex. "Because our new ARIES assays are being developed with a universal protocol, allowing laboratories to quickly run C. diff and norovirus at the same time, more rapid patient management techniques can be implemented to stem potentially costly outbreak situations and improve patient care."

With a strong track record as an innovator and as a leader in molecular diagnostics, Luminex Corporation was the first company to commercialize an FDA cleared norovirus test as a part of its comprehensive syndromic xTAG® Gastrointestinal Pathogen Panel (GPP).

Luminex Corporation will soon be the first company to offer multiplexed molecular panels such as GPP as well as rapid, sample-to-answer testing with the introduction of its new ARIES system and menu of assays. This combination will provide hospital labs and their clinicians with the most comprehensive suite of tools available to help manage patients with diarrheal disease.

Luminex will feature its new ARIES System at the Clinical Virology Symposium (CVS), April 27–30 in Daytona Beach, FL, Booth #209. Additionally, during CVS they will host a workshop on Monday, April 28th from 2:45pm - 4:15pm EST, demonstrating the value of xTAG GPP for community-acquired diarrhea, and the burden of norovirus in the hospital setting.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
Department of Defense award accelerates development of Luminex bio-threat detection technology program.
Thursday, August 16, 2012
Luminex Corporation Announces Agreement to Acquire GenturaDx
Acquisition accelerates development of integrated sample-to-answer system for molecular diagnostics.
Monday, July 09, 2012
Luminex Corporation Announces Agreement to Acquire EraGen Biosciences
Acquisition expands molecular diagnostic and infectious disease capabilities.
Wednesday, June 22, 2011
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Best Test to Diagnose Strangles in Horses Identified
New research by Dr. Ashley Boyle of New Bolton Center’s Equine Field Service team shows that the best method for diagnosing Strangles in horses is to take samples from a horse’s guttural pouch and analyze them using a loop-mediated amplification (LAMP) polymerase chain reaction (PCR) test.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
Detecting When Hormone Treatment for Breast Cancer Stops Working
Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment.
Packaging and Unpacking of the Genome
New research improves understanding of the importance of histone replacement.
New Way to Find DNA Damage
University of Utah chemists devised a new way to detect chemical damage to DNA that sometimes leads to genetic mutations responsible for many diseases, including various cancers and neurological disorders.
How Different Treatments for Crohn's Effect the Microbiome
Different treatments for Crohn's disease in children affects their gut microbes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.
Charting the 'Genomic Biography' of Leukemia
A new study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard offers a glimpse of the wealth of information that can be gleaned by combing the genome of a large collection of leukemia tissue samples.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos